Theravance Biopharma Inc TBPH 深 沪
等待开盘 10-09 09:30:00 美东时间
17.03
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 17.03
- 总市值 8.84亿
- 52周最高 21.03
- 市盈率 静 8.28
- 换手率 0.00%
- 52周最低 13.08
- 委 比 0.00%
- 总股本 5191.88万
- 历史最高 43.44
- 量 比 0
- 振 幅 0.00%
- 历史最低 6.10
- 每 手 1
- 风险率 1.71%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Vir Biotechnology names Aziz Sawaf as CFO
Vir Biotechnology (VIR) has appointed Aziz Sawaf as executive vice president and chief financial officer, effective October 5, 2026, to lead the finance, IT, and investor relations functions. Sawaf b...
10-01 20:38
Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal
Zymeworks Inc. (NASDAQ:ZYME) on Monday finalized its acquisition of Theravance Biopharma, releasing final transaction details and updated financial guidance for fiscal year 2026. The biotechnology company projects 2026 revenue between $278 million and $292 million, alongside 2026 adjusted EBITDA ran...
09-29 01:05
Zymeworks outlines guidance following Theravance acquisition
Zymeworks (ZYME) Monday reported the final transaction details and updated financial guidance following the completion of its acquisition of Theravance Biopharma. The acquisition adds YUPELRI (revefen...
09-28 18:51
Zymeworks Guides FY26 Total Sales, Including Collaboration Revenue From YUPELRI, Of $278M-$292M And Adjusted EBITDA Of $114M-$128M
Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the final transaction details and updated financial guidance following the completion of its acquisi...
09-28 18:12
BTIG Suspends Neutral Rating on Theravance Biopharma
BTIG suspends Neutral rating on Theravance Biopharma (NASDAQ:TBPH).
09-24 17:25
Theravance Biopharma Completes Merger and Plans Nasdaq Delisting
Theravance Biopharma ( ($TBPH) ) has issued an update. Theravance Biopharma com...
09-24 04:50
Zymeworks Completes Acquisition of Theravance Biopharma
Zymeworks Inc. has completed the acquisition of Theravance Biopharma, enhancing its strategy to build a diversified biotechnology company. A conference call discussing the acquisition details will be held on September 28 at 8:30 am ET. Zymeworks combines innovative R&D with growing commercial assets, including YUPELRI® and Ziihera®, leveraging its Azymetric™ platform for next-generation antibody technologies.
09-23 20:01
Catalyst Watch: FOMC blockbuster, Salesforce event, and 24-hour trading talk
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. Monday - September...
09-12 03:00
Theravance facing several lawsuits seeking to block Zymeworks acquisition
Theravance Biopharma (TBPH) is facing at least three lawsuits that aim to scuttle its planned $929M acquisition by Zymeworks (ZYME). The legal actions seek to enjoin Theravance from proceeding with th...
09-10 23:03
Theravance Biopharma issues disclosures amid Zymeworks merger
Theravance Biopharma ( ($TBPH) ) just unveiled an update. On June 28, 2026, The...
09-10 21:27
